CS MEDICA A/S (“CS MEDICA” or the “Company”) announces that the resolutions passed at its Extraordinary General Meeting (EGM) held on July 31, 2024, together with the issuance of bonus warrants following §3.1.4.2 of the Articles of Association, have now been registered with the Danish Companies Registration Office.

As a result, the Company’s share capital has increased from DKK 854,022.28 to DKK 897,342.84, with the total number of registered shares increasing by 1,482,670 shares, accumulating to a total of 13,805,305 shares in CS MEDICA.

For more information about CS MEDICA, please contact:
Gitte Lund Henriksen, CFO
Phone: + (45) 2774 2280
Email: glh@cs-medica.com
Website: https://www.cs-medica.com/
 

CS MEDICA A/S is a Danish-based MedTech company specializing in research, development, manufacturing, and commercialization within the pharmaceutical industry. The company focuses on innovative substance-based medical devices containing bioactive CBD for the treatment of arthritis, pain, insomnia, psoriasis, wounds, and hay fever. Combining science and nature, CS MEDICA aims to create over-the-counter treatments to combat autoimmune and stress-related diseases, leveraging knowledge of the endocannabinoid system, patient needs, and extensive experience in the pharmaceutical industry. Pioneering scientific breakthroughs, the company works to expand access to its treatments, understand patient needs globally, and alleviate the pain caused by the diseases it addresses. With IP Rights secured and several products already approved along with more in the pipeline, CS MEDICA is well-positioned in a rapidly growing market. CS MEDICA is listed on the Spotlight Stock Market in Stockholm (symbol: “CSMED”). For more information, visit cs-medica.com and LinkedIn.